SCHEMBL5647264

SCHEMBL5647264

Cc1c(Cc2ccc(F)cc2)c(=O)oc2cc(O)ccc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 6/20 0.77
KDM4E B2RXH2 4/20 0.77
GLA P06280 3/20 0.77
GAA P10253 3/20 0.77
NPSR1 Q6W5P4 1/20 0.77
ERAP1 Q9NZ08 1/20 0.77
TP53 P04637 2/20 0.66
BRAF P15056 1/20 0.64
MAP2K1 Q02750 1/20 0.64
ALDH1A1 P00352 3/20 0.58
HPGD P15428 2/20 0.58
CASP1 P29466 2/20 0.58
CASP7 P55210 2/20 0.58
HSD17B10 Q99714 2/20 0.58
TSHR P16473 1/20 0.58
ESR1 P03372 3/20 0.55
AR P10275 1/20 0.55
NQO1 P15559 2/20 0.55
ACHE P22303 1/20 0.54
MAOB P27338 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1590671 0.87 HSD17B3 (0.77) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL14246785 0.87 HSD17B3 (0.77) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL971942 0.87 KDM4E (1.00) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL28668975 0.85 HSD17B3 (0.73) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL13391475 0.85 HSD17B3 (0.73) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL960393 0.83 HSD17B3 (0.70) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL5648321 0.82 HSD17B3 (0.70) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL12204224 0.81 HSD17B3 (0.68) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL15931615 0.81 HSD17B3 (0.68) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL15931623 0.81 HSD17B3 (0.79) HSD17B3KDM4EGLAGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108658962-B 3-substituted coumarin furazan derivative and application thereof in preparation of multidrug-resistant tumor drugs 复旦大学 2021-10-01 CN disclosed
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL HSD17B3 56/4885KDM4E 3457/4885GLA 107/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL HSD17B3 33/4885KDM4E 3778/4885GLA 118/4885
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 HSD17B3 3885/4885KDM4E 4656/4885GLA 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.